TY - JOUR AU - Tamimi, Yahya AU - Al-Harthy, Sheikha AU - Al-Haddabi, Ibrahim AU - Al-Kindi, Mohammed AU - Babiker, Hamza AU - Al-Moundhri, Mansour AU - Burney, Ikram PY - 2014/02/01 Y2 - 2024/03/28 TI - The p53 Mutation/Deletion Profile in a Small Cohort of the Omani Population with Diffuse Large B-Cell Lymphoma JF - Sultan Qaboos University Medical Journal JA - Sultan Qaboos Univ Med J VL - 14 IS - 1 SE - Original Studies DO - UR - https://journals.squ.edu.om/index.php/squmj/article/view/1883 SP - 50-58 AB - <span>Objectives:</span><span> Mutations/deletions affecting the </span><span>TP53</span><span> gene are considered an independent marker predicting a poor prognosis for patients with diffuse large B-cell lymphoma (DLBCL). A cohort within a genetically isolated population was investigated for </span><span>p53</span><span> mutation/deletion status. </span><span>Methods:</span><span>Deoxyribonucleic acid (DNA) samples were extracted from 23 paraffin-embedded blocks obtained from DLBCL patients, and subjected to polymerase chain reaction (PCR) amplification and sequencing of exons 4–9 of the </span><span>p53</span><span> gene. </span><span>Results:</span><span> While 35% of patients analysed displayed allelic deletions (</span><span>P</span><span>&lt;0.01), immunohistochemical analysis revealed a mutation rate of 69.5%. It is noteworthy that the rate of </span><span>p53</span><span> mutations/deletions in this small cohort was found to be higher than that previously reported in the literature. Interestingly, patients with </span><span>p53</span><span> mutations displayed a better overall survival when compared to those without. The survival of patients treated with rituximab-containing combination chemotherapy was significantly better than those who did not receive rituximab (</span><span>P</span><span> &lt;0.05). Furthermore, a modelling analysis of the deleted form of </span><span>p53</span><span> revealed a huge structural change affecting the DNA-binding domain.</span><span> Conclusion:</span><span> The </span><span>TP53</span><span> mutation/deletion status plays a role in mechanism(s) ruling the pathogenesis of DLBCL and may be useful for stratifying patients into distinct prognostic subsets.</span><br /><br /> ER -